BiotechTube

Rosuvamibe + Monorova

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Atherosclerotic Cardiovascular Disease

Conditions

Atherosclerotic Cardiovascular Disease, Type 2 Diabetes

Trial Timeline

Mar 27, 2018 → Dec 1, 2021

NCT ID
NCT03403556

About Rosuvamibe + Monorova

Rosuvamibe + Monorova is a approved stage product being developed by Yuhan for Atherosclerotic Cardiovascular Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT03403556. Target conditions include Atherosclerotic Cardiovascular Disease, Type 2 Diabetes.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT03597412ApprovedCompleted
NCT03403556ApprovedUNKNOWN
NCT03494270ApprovedCompleted

Competing Products

20 competing products in Atherosclerotic Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
Rosuvamibe + MonorovaYuhanApproved
85
Lepodisiran Sodium + PlaceboEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 3
77
Placebo + AZD0780AstraZenecaPhase 2
52
Clopidogrel + TicagrelorAstraZenecaApproved
85
Epanova® (omega-3 carboxylic acids) + corn oil controlAstraZenecaPhase 3
77
atorvastatin + placeboMerckPhase 1
33
Anacetrapib + Placebo anacetrapibMerckPhase 3
77
Atorvastatin + Simvastatin + Rozuvastatin + Ezetimibe + Niacin + Ciprofibrate + Fenofibrate + Bezafibrate + Evolocumab + Alirocumab + InclisiranNovartisPre-clinical
23
Ranolazine 500 mgNovartisPhase 2
52
Inclisiran + Background lipid lowering therapyNovartisPhase 3
77
Inclisiran + EvolocumabNovartisPhase 2
52
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5mlNovartisPhase 3
77
atorvastatin + inclisiranNovartisApproved
85
TQJ230 + PlaceboNovartisPhase 3
77
Inclisiran + PlaceboNovartisPhase 3
77
PelacarsenNovartisPre-clinical
23
InclisiranNovartisPhase 3
77
InclisiranNovartisApproved
85
Pelacarsen (TQJ230)NovartisPhase 3
77

Other Products from Yuhan

generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85